Sirius Collaborates with Vanderbilt on PGx Test | GenomeWeb

NEW YORK (GenomeWeb News) – Diagnostics developer Sirius Genomics will collaborate with Vanderbilt University to study patients in a biomarker study for a drug aimed at treating severe sepsis, the company said today.

The pharmacogenomics company will work with Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study to continue development of a diagnostic to assess responsiveness to recombinant human activated Protein C. The drug is sold by Eli Lilly under the trade name Xigris.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.